AbCellera and IGM Biosciences (NASDAQ:IGMS) entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies.
AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using its full-stack, AI-powered antibody discovery technology.
Financial terms of the collaboration were not disclosed.
“Engineered IgM and IgA antibodies may be able to overcome some of the limitations of the current IgG-based therapeutics, and this partnership demonstrates the depth of our commitment to ensuring that the potential of our IgM and IgA technology platform is fully realized in areas of high unmet medical need.” said Fred Schwarzer, CEO of IGM Biosciences.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.